206 related articles for article (PubMed ID: 26845116)
21. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
[TBL] [Abstract][Full Text] [Related]
22. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
23. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
24. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
Velizheva NP; Rechsteiner MP; Wong CE; Zhong Q; Rössle M; Bode B; Moch H; Soltermann A; Wild PJ; Tischler V
Cancer Cytopathol; 2017 Jan; 125(1):30-40. PubMed ID: 27636102
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer.
Gow CH; Liu YN; Li HY; Hsieh MS; Chang SH; Luo SC; Tsai TH; Chen PL; Tsai MF; Shih JY
Neoplasia; 2018 Aug; 20(8):838-847. PubMed ID: 30015159
[TBL] [Abstract][Full Text] [Related]
26. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
27. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
28. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
[TBL] [Abstract][Full Text] [Related]
29. Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients.
Descarpentries C; Leprêtre F; Escande F; Kherrouche Z; Figeac M; Sebda S; Baldacci S; Grégoire V; Jamme P; Copin MC; Tulasne D; Cortot AB
J Thorac Oncol; 2018 Dec; 13(12):1873-1883. PubMed ID: 30195702
[TBL] [Abstract][Full Text] [Related]
30. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
[TBL] [Abstract][Full Text] [Related]
31. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Davies KD; Lomboy A; Lawrence CA; Yourshaw M; Bocsi GT; Camidge DR; Aisner DL
J Thorac Oncol; 2019 Apr; 14(4):737-741. PubMed ID: 30639620
[TBL] [Abstract][Full Text] [Related]
32. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.
Takeuchi K; Choi YL; Soda M; Inamura K; Togashi Y; Hatano S; Enomoto M; Takada S; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
Clin Cancer Res; 2008 Oct; 14(20):6618-24. PubMed ID: 18927303
[TBL] [Abstract][Full Text] [Related]
33. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
[TBL] [Abstract][Full Text] [Related]
34. A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer.
Karlsson A; Cirenajwis H; Ericson-Lindquist K; Brunnström H; Reuterswärd C; Jönsson M; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Micke P; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
Sci Rep; 2019 Mar; 9(1):5207. PubMed ID: 30914778
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
36. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
37. A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.
Bret D; Chappuis V; Poncet D; Ducray F; Silva K; Mion F; Vasiljevic A; Ferraro-Peyret C; Mottolese C; Leblond P; Gabut M; Frappaz D; Streichenberger N; Meyronet D; Bringuier PP; Barritault M
Mol Diagn Ther; 2019 Aug; 23(4):537-545. PubMed ID: 31087282
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.
Li S; Choi YL; Gong Z; Liu X; Lira M; Kan Z; Oh E; Wang J; Ting JC; Ye X; Reinhart C; Liu X; Pei Y; Zhou W; Chen R; Fu S; Jin G; Jiang A; Fernandez J; Hardwick J; Kang MW; I H; Zheng H; Kim J; Mao M
J Thorac Oncol; 2016 Dec; 11(12):2129-2140. PubMed ID: 27615396
[TBL] [Abstract][Full Text] [Related]
39. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
40. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
Zhang S; Yan B; Zheng J; Zhao J; Zhou J
Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
